How MK-677 (Ibutamoren) Affects Fasting Insulin

MK-677 elevates fasting insulin through the same core mechanism as exogenous GH (compensatory hyperinsulinemia driven by insulin resistance), but with pharmacological features that may intensify the effect:

1. Continuous GH stimulation and sustained lipolysis: Unlike exogenous GH injections that produce a pharmacological pulse followed by a trough, MK-677 stimulates GH release continuously over 24 hours. This creates sustained elevation of circulating free fatty acids (FFAs) from adipose tissue lipolysis. Persistent FFA elevation drives chronic Randle cycle suppression of glucose oxidation in skeletal muscle, forcing the muscle to burn fat instead of glucose.
2. Unrelenting insulin resistance: Physiological and injected GH both allow periods of insulin sensitivity recovery between pulses. MK-677 eliminates these recovery windows, creating a state of continuous peripheral insulin resistance. The pancreatic beta cells must increase insulin output persistently, not just in response to transient GH peaks.
3. Direct ghrelin receptor effects on the pancreas: The GHS-R1a (ghrelin receptor) is expressed on pancreatic beta cells. MK-677's activation of this receptor directly modulates insulin secretion. Research suggests that ghrelin signalling can both stimulate and inhibit insulin release depending on the metabolic context, adding complexity to MK-677's metabolic profile.
4. Appetite-driven caloric excess: MK-677 significantly increases appetite through hypothalamic ghrelin receptor activation. If this appetite increase leads to higher carbohydrate intake, the resulting post-prandial glucose spikes require additional insulin secretion, compounding the pharmacological hyperinsulinemia.

The Nass et al. (2008) 12-month RCT at 25 mg/day documented increased fasting insulin in the treatment group, confirming that MK-677's theoretical mechanisms translate to measurable clinical effects.

Low dose (10-15 mg/day):

• Fasting insulin may rise modestly to 8-15 mIU/L
• HOMA-IR typically stays below 2.0 in lean, active individuals
• Beta-cell compensation is adequate at this dose for most users
• Effects begin within 2-4 weeks of starting

Standard dose (25 mg/day):

• Fasting insulin commonly rises to 12-25 mIU/L
• HOMA-IR frequently enters the 1.5-2.5 range
• Compensatory hyperinsulinemia is clearly established
• Individual variation is substantial: some users see minimal changes, others develop significant insulin resistance

High dose or prolonged use (25 mg/day for 6+ months):

• Fasting insulin can reach 20-30+ mIU/L in susceptible individuals
• HOMA-IR may exceed 2.5-3.0
• Risk of beta-cell fatigue increases with duration
• The Nass et al. trial showed progressive metabolic changes over 12 months

Onset and progression:

• Fasting insulin begins rising within 2-4 weeks (faster than HbA1c changes)
• HOMA-IR trends upward progressively over months
• As with exogenous GH, insulin rises before glucose: normal glucose with rising insulin is the earliest warning sign

Comparison with exogenous GH: At equivalent IGF-1 levels, MK-677 may produce slightly higher fasting insulin due to the continuous (non-pulsatile) GH stimulation pattern. However, direct head-to-head comparative data are limited.

Baseline: Obtain fasting insulin and fasting glucose before starting MK-677. Calculate baseline HOMA-IR. Both markers must be measured in a truly fasted state (10-12 hours, water only). Even black coffee can affect insulin levels.

During use:

• Fasting insulin + fasting glucose at 4 weeks (early detection of insulin resistance)
• Then every 3-6 months, always calculating HOMA-IR
• HbA1c every 3 months as a complementary chronic marker
• Track the HOMA-IR trend over time; a consistently rising trajectory is more concerning than any single value

HOMA-IR targets for lean athletes on MK-677:

• Below 1.0: excellent, no intervention needed
• 1.0-1.5: normal, monitor and optimise diet
• 1.5-2.0: mild insulin resistance, begin dietary and supplement interventions
• 2.0-2.5: moderate insulin resistance, consider dose reduction and/or metformin
• Above 2.5: significant insulin resistance, dose reduction strongly recommended

Early detection strategy: Because MK-677 users often self-administer without medical supervision, HOMA-IR trending above 1.5 in a lean, active athlete should be the trigger for proactive intervention. Do not wait for fasting glucose to rise; that is a late finding.

Practical considerations: MK-677 is often taken at bedtime to coincide with natural nocturnal GH release. Morning fasting blood draws naturally capture the metabolic state after overnight MK-677 exposure, providing a relevant assessment window.

Dose reduction is first-line:

• If HOMA-IR exceeds 2.0, reduce MK-677 to the minimum effective dose (often 10-12.5 mg)
• The dose-insulin resistance relationship is approximately linear: halving the dose meaningfully reduces insulin resistance

Cycling strategies:

• 5 days on / 2 days off allows 48 hours of insulin sensitivity recovery each week
• 8 weeks on / 4 weeks off limits cumulative metabolic exposure
• Some users take MK-677 only on training days (3-5 days/week) to balance GH benefits with metabolic health

Dietary management (critical for MK-677 due to appetite effects):

• Pre-plan meals to prevent appetite-driven overconsumption of carbohydrates
• High-protein, high-fibre meals maximise satiety and minimise glucose impact
• If dosing at bedtime, ensure dinner is lower in simple carbohydrates
• Carbohydrate timing around workouts exploits exercise-mediated insulin-independent glucose uptake

Supplement support:

• Berberine 500 mg 2-3x daily with meals (AMPK activator, evidence-based insulin sensitiser)
• Chromium picolinate 200-1000 mcg/day (enhances insulin receptor activity)
• Alpha-lipoic acid 300-600 mg/day (improves insulin signalling in skeletal muscle)

Pharmaceutical options:

• Metformin 500-1000 mg/day if HOMA-IR exceeds 2.0 despite lifestyle measures
• Extended-release formulation preferred for tolerability
• Metformin directly counteracts hepatic glucose output and improves peripheral insulin sensitivity

When to reconsider MK-677:

• If HOMA-IR exceeds 2.5 despite dose reduction and interventions, MK-677 may not be metabolically appropriate for you
• Consider switching to low-dose exogenous GH (2-3 IU/day), which provides pulsatile GH exposure with potentially less metabolic disruption
• Individual metabolic tolerance varies significantly; some people simply do not tolerate MK-677's continuous GH stimulation pattern